Q-Line Biotech IPO Subscription Status Day-2: Live Bidding

Q-Line Biotech IPO subscription opened on Thursday, May 21, 2026 and will remain open until May 25, 2026. The company plans to raise around ₹214 crores through the IPO route. The investor allocation includes 35% reserved for retail investors, 50% for QIBs, and 15% for NII investors. The price band for the Q-Line Biotech IPO has been fixed at ₹326 to ₹343 per equity share.

The minimum market lot for the Q-Line Biotech IPO is 800 shares, requiring an application amount of ₹2,74,400. The issue is categorized as an SME IPO and is proposed to be listed on NSE SME.

Q-Line Biotech IPO Subscription Status – Day 2

Company overview

Q-Line Biotech is an Indian In-Vitro Diagnostics (IVD) company founded in 2008 with its headquarters located in Lucknow, Uttar Pradesh. The company is engaged in the manufacturing, development, and supply of diagnostic products, laboratory equipment, rapid testing solutions, and pathology instruments for the healthcare industry. Under the “Make in India” initiative, Q-Line Biotech focuses on domestic production of advanced healthcare products including hematology reagents, magnetic beads, gold nanoparticles, ELISA kits, urine testing strips, and multiple biochemistry diagnostic solutions.

The company caters to hospitals, diagnostic centers, medical institutions, pathology laboratories, and healthcare organizations across India and international markets. Q-Line Biotech has expanded its global footprint by exporting products to over 50 countries. The company maintains strong quality standards and operates with certifications such as ISO 9001:2015 and ISO 13485:2016. Through continuous innovation, modern manufacturing practices, and a focus on accessible healthcare diagnostics, Q-Line Biotech continues to strengthen its presence in the medical diagnostics and laboratory solutions sector.